Literature DB >> 2916941

The desmoid tumor. Not a benign disease.

M C Posner1, M H Shiu, J L Newsome, S I Hajdu, J J Gaynor, M F Brennan.   

Abstract

The necessity of aggressive therapy for desmoid tumors has not been clearly established. To evaluate the therapeutic value of adequate resection and radiation therapy, we conducted a retrospective study of 138 patients treated from 1965 through 1984. Univariate analysis revealed five factors predictive of local failure: (1) age between 18 and 30 years, (2) presentation with recurrent disease, (3) partial or limited margin excision, (4) tumor at or close to the microscopic margin of resection, and (5) radiation therapy not administered for gross residual disease. Multivariate analysis identified two of these factors as having independent predictive value for recurrence: (1) presentation with recurrent disease and (2) less-than-adequate margins of resection. The five-year survival probability was 92%, but 11 of the 138 patients died as a consequence of locally uncontrolled tumor. These findings confirm that desmoid tumors are malignant soft-tissue neoplasms that warrant aggressive therapy.

Entities:  

Mesh:

Year:  1989        PMID: 2916941     DOI: 10.1001/archsurg.1989.01410020061010

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  47 in total

1.  Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors).

Authors:  B A Alman; C Li; M E Pajerski; S Diaz-Cano; H J Wolfe
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Recurrence patterns and management options in aggressive fibromatosis.

Authors:  Rajaraman Ramamurthy; Balasubramanian Arumugam; Balasubramaniam Ramanandham
Journal:  Indian J Surg Oncol       Date:  2012-05-12

3.  Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.

Authors:  Daniel Robert Quast; Ralph Schneider; Emanuel Burdzik; Steffen Hoppe; Gabriela Möslein
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

4.  Wide resection of the upper right hemithorax combined with amputation of the right arm for a recurrent desmoid tumor.

Authors:  Yasushi Sakamaki; Tetsuo Kido; Motoaki Yasukawa; Takashi Fujiwara; Katsuki Kuwae; Motomu Maeda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2006-08

5.  Intracranial aggressive fibromatosis presenting as panhypopituitarism and diabetes insipidus.

Authors:  A Gursoy; M Cesur; B Aktaş; G Utkan; V Tonyukuk Gedik; Mf Erdogan; N Kamel
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

6.  Extra-abdominal fibromatosis (desmoid tumor) arising in the infratemporal fossa: a case report.

Authors:  M Corsten; P Donald; J Boggan; A Gadre; R Gandour-Edwards; W Nemzek
Journal:  Skull Base Surg       Date:  1998

Review 7.  Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases.

Authors:  A Montero Luis; R Hernanz de Lucas; A Hervás Morón; E Fernández Lizarbe; S Sancho García; C Vallejo Ocaña; A Polo Rubio; A Ramos Aguerri
Journal:  Clin Transl Oncol       Date:  2008-06       Impact factor: 3.405

8.  MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

Authors:  Firouzeh Kamali; Wei-Lien Wang; B A Guadagnolo; Patricia S Fox; Valerae O Lewis; Alexander J Lazar; Anthony P Conley; Vinod Ravi; Mohammad Toliyat; Harshad S Ladha; Brian P Hobbs; Behrang Amini
Journal:  Br J Radiol       Date:  2015-11-18       Impact factor: 3.039

9.  Multicentric extra-abdominal desmoid tumors arising in bilateral lower limbs.

Authors:  Tokiko Shimoyama; Koji Hiraoka; Takanori Shoda; Tetsuya Hamada; Nobuhiro Fukushima; Kensei Nagata
Journal:  Rare Tumors       Date:  2010-03-31

10.  Huge intrathoracic desmoid tumor.

Authors:  Majdi Ibrahim; Hasan Sandogji; Abdullah Allam
Journal:  Ann Thorac Med       Date:  2009-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.